This article provides comprehensive information on the AstraZeneca Stock Price Prediction. (AstraZeneca Stock Price Prediction 2025, 2026, 2030, 2040, 2050). Let’s get started.
AstraZeneca is a huge company that makes medicines to make people feel better. It started in 1992 when two companies from Sweden and the U.K. came together.
Their head office is in Cambridge, England. AstraZeneca works hard to find new medicines and sell them to doctors so they can help patients.
They work on making medicines for diseases like cancer, heart, kidney, respiratory, and immune system diseases.
Many people who invest money in the company watch how its stock (or shares) perform to see if it grows and succeeds.
This blog examines money information and market trends to predict AstraZeneca’s stock price from 2025 to 2050.
In this blog, we will explain what people think the stock price of AstraZeneca will be over the next 25 years, from 2025 to 2050.
What is AstraZeneca PLC NYSE: (AZN)?
AstraZeneca is a large company in Britain and Sweden that makes specialty medicines to make people feel better.
They make medicines for things like cancer, heart and blood problems, stomach problems, brain conditions, respiratory problems, and different health problems like inflammation and immune system problems, so hospitals and doctors can give them to patients.
Their most famous medicines include Tagrisso, Imfinzi, Lynparza, Calquence, and Farxiga.
They work hard to find new and better ways to make medicines, making them one of the top companies in the world. AstraZeneca works worldwide, helping to improve the health of many people everywhere, in many different countries.
Company Overview
| Company Name | AstraZeneca Plc |
| Stock Name | AstraZeneca plc |
| Founded in | LON: AZN (AZN: LSE) |
| Headquarters | Cambridge, United Kingdom |
| Founder | Pascal Claude Roland Soriot |
| Current Share Price | $67.20 |
| Industry | Pharmaceuticals and Biotechnology |
| Revenue | $45.8 billion |
| Market Capitalization | $208.36 billion |
| Primary Exchange | LON: AZN (AZN:LSE) |
| Employees | 94,300+ |
| Official Website | https://www.astrazeneca.com |
Fundamental Data
| Metric | Value |
|---|---|
| Market Cap | $219.49B |
| Enterprise Value | $244.13B |
| Trailing P/E | 34.20 |
| Forward P/E | 15.60 |
| PEG Ratio (5yr expected) | 0.79 |
| Price/Sales | 4.33 |
| Price/Book | 5.49 |
| Profit Margin | 12.69% |
| Operating Margin (ttm) | 20.41% |
| Revenue (ttm) | $51.22B |
| Gross Profit (ttm) | $42.4B |
| EBITDA | $18.49B |
| Net Income (ttm) | $6.6B |
| Diluted EPS (ttm) | $2.08 |
| Total Cash (mrq) | $4.94B |
| Total Debt (mrq) | $31.62B |
| Debt/Equity Ratio | 77.48% |
| Operating Cash Flow (ttm) | $11.34B |
| Levered Free Cash Flow (ttm) | $9.52B |
| Beta (5Y Monthly) | 0.19 |
| 52-Week High | $87.69 |
| 52-Week Low | $60.48 |
| Annual Dividend Rate | $1.59 |
| Dividend Yield | 2.11% |
| Payout Ratio | 71.58% |
AstraZeneca Stock Price History
| Period | Stock Price (USD) |
|---|---|
| 6 Months Ago | $87.63 |
| 1 Year Ago | $65.53 |
| 5 Years Ago | $54.52 |
| All-Time High | $87.63 |
AstraZeneca Stock Price Today
| Day | Minimum Price | Maximum Price |
| Today | -₹4.16 | +₹42.14 |
AstraZeneca Share Price Prediction Tomorrow
This large pharmaceutical company is very good at creating new and advanced medicines. They focus on helping people with cancer, heart problems, kidney problems, metabolism (how the body uses energy), breathing problems, and immune system problems.
The company works hard to discover new medicines, works with other companies to make improvements, and always looks for new areas to help people. Because of this, they are growing and getting bigger.
| Day | Minimum Price | Maximum Price |
| Tomorrow | -$3.8 | +$5.7 |
AZN Indicator-Based Technical Analysis
NOTE!
The signals depend on how long you want to keep your money invested. If you want to buy AZN and hold it for more than a week, it is best to look for signals from weekly and daily charts. But if you want to buy and sell quickly, signals from shorter time frames like 5 minutes to 1 hour are better.
ASML Stock Price Prediction 2025, 2026, 2030, 2040, 2050
AstraZeneca Stock Price Forecast
| Year | Minimum Price | Maximum Price |
| 2025 | $51 | $112 |
| 2026 | $75 | $151 |
| 2027 | $91 | $202 |
| 2028 | $151 | $261 |
| 2029 | $202 | $332 |
| 2030 | $271 | $445 |
| 2040 | $1002 | $1402 |
| 2050 | $1902 | $2602 |
AstraZeneca Stock Price Forecast
AstraZeneca Stock Price Prediction 2025
The company spends a lot of money on creating new medicines, focuses on areas where it can help the most people, and does a lot of new research.
They focus on helping people with serious illnesses like cancer and rare diseases, which will help the company make more money. This allows them to remain a big and strong pharmaceutical company.
They keep coming up with new ideas and sell their medicines in more and more countries, which helps them grow.
In 2025, AstraZeneca thinks its stock will go up. We believe that 2025 the company’s stock (like its Price) will be $112 because of all these good things.
We believe that in 2025 its stock will be worth between $51 and $112.
| Year | Minimum Price | Maximum Price |
| 2025 | $51 | $112 |
| Month | Minimum Price | Maximum Price |
| January | $56 | $81 |
| February | $54 | $72 |
| March | $51 | $66 |
| April | $57 | $74 |
| May | $61 | $77 |
| June | $65 | $84 |
| July | $68 | $86 |
| August | $71 | $87 |
| September | $74 | $85 |
| October | $77 | $89 |
| November | $81 | $99 |
| December | $91 | $112 |
AstraZeneca Stock Price Prediction 2026
By 2026, the company will be doing well worldwide, especially helping people with cancer and rare diseases. They invest in innovative computer technology, AI, to create new medicines faster.
They also have many new medicines almost ready to help patients. The company can also start selling in new countries that are still growing.
Because of all these good things, the company can become more valuable. Overall, AstraZeneca is becoming a top leader in finding ways to make healthcare better and more sustainable for the future, and its stock price can reach $151 in 2026.
Depending on what we think, the stock price in the year 2026 can be between $75 and $150.
| Year | Minimum Price | Maximum Price |
| 2026 | $75 | $151 |
| Month | Minimum Price | Maximum Price |
| January | $91 | $119 |
| February | $84 | $112 |
| March | $79 | $102 |
| April | $75 | $104 |
| May | $81 | $120 |
| June | $95 | $122 |
| July | $101 | $119 |
| August | $104 | $122 |
| September | $111 | $126 |
| October | $119 | $132 |
| November | $128 | $144 |
| December | $134 | $151 |
AstraZeneca Stock Price Prediction 2027
This company is getting better at making medicines for cancer and rare diseases. As more treatments are being developed and new drugs are coming out soon, they will make more money.
The company will do better as more people need their medicines and the market grows. Therefore, the company’s stock price will be $202 by 2027.
We believe the company’s stock price will be between $91 and $202 in 2027.
| Year | Minimum Price | Maximum Price |
| 2027 | $91 | $202 |
| Month | Minimum Price | Maximum Price |
| January | $135 | $164 |
| February | $126 | $132 |
| March | $118 | $129 |
| April | $109 | $116 |
| May | $91 | $102 |
| June | $95 | $112 |
| July | $100 | $120 |
| August | $113 | $129 |
| September | $121 | $138 |
| October | $132 | $156 |
| November | $147 | $190 |
| December | $171 | $202 |
AstraZeneca Stock Price Prediction 2028
The company is getting bigger worldwide and finding new ways to fight cancer, which will help it make more money.
It uses a special science called gene therapy and makes medicines for each individual, which makes it different from other companies.
The company keeps investing money in new ideas and keeps buying other companies to get better. We think the company’s stock price will be $261 by 2028.
We think the stock price 2028 will be between $151 and $261.
| Year | Minimum Price | Maximum Price |
| 2028 | $151 | $261 |
| Month | Minimum Price | Maximum Price |
| January | $171 | $211 |
| February | $164 | $181 |
| March | $151 | $187 |
| April | $168 | $199 |
| May | $179 | $211 |
| June | $181 | $209 |
| July | $187 | $220 |
| August | $198 | $230 |
| September | $221 | $242 |
| October | $230 | $250 |
| November | $239 | $256 |
| December | $248 | $262 |
AstraZeneca Stock Price Prediction 2029
The company is developing new medicines, primarily for serious illnesses like cancer and rare diseases, which are expected to help it make more money as it grows.
They are working on essential medicines for cancer, heart, kidney, and respiratory problems, which will help them make more money in the coming years.
Also, they are developing new medicines to grow and stay ahead of other companies. We predict the company’s stock price will be $332 in 2029.
We believe the specific value in 2029 will be between $202 and $332.
| Year | Minimum Price | Maximum Price |
| 2029 | $202 | $332 |
| Month | Minimum Price | Maximum Price |
| January | $248 | $274 |
| February | $221 | $256 |
| March | $202 | $241 |
| April | $229 | $261 |
| May | $240 | $256 |
| June | $247 | $269 |
| July | $251 | $280 |
| August | $264 | $287 |
| September | $2734 | $291 |
| October | $283 | $299 |
| November | $291 | $319 |
| December | $311 | $332 |
AstraZeneca Stock Price Prediction 2030
The company wants to make a lot of money by 2030 – a goal of $80 billion, which is way more than the $45.8 billion it made in 2023. To do this, they plan to create 20 new medicines, and 10 of them will help cure cancer.
They are making significant advances in cancer treatments and new therapies that use special drugs involving small cells and other drugs. Because of these advances, the company is growing rapidly, with its money growing by 19% and its cancer treatments growing by 26%.
By creating personalized treatments for patients and buying other companies to help develop them, AstraZeneca is becoming a leader in creating new, better medicines worldwide.
Based on this, experts believe that by 2030, the company’s stock (which is like a share of the company you can buy) will be worth about $445.
Depending on what we think, the stock price will be between $271 and $445 in 2030.
| Year | Minimum Price | Maximum Price |
| 2030 | $271 | $445 |
| Month | Minimum Price | Maximum Price |
| January | $311 | $344 |
| February | $284 | $299 |
| March | $271 | $291 |
| April | $282 | $329 |
| May | $319 | $346 |
| June | $332 | $361 |
| July | $344 | $379 |
| August | $351 | $391 |
| September | $366 | $401 |
| October | $380 | $411 |
| November | $391 | $430 |
| December | $421 | $445 |
AstraZeneca Stock Price Prediction 2040
By 2040, this company plans to become a prominent leader in creating new medicines explicitly tailored for each individual using intelligent computers and new scientific tricks.
They want to be the best at fixing genes, delivering personalized treatments, and inventing new ways to help sick people. They spend much money on research, buy other biotech companies, and work with different teams to stay on top.
The company also cares about protecting the environment and helping people with rare diseases. Because of all these efforts, their value or “stock price” is projected to be around $1402 in 2040.
We believe the stock price will be between $1002 and $1402 in 2040.
| Year | Minimum Price | Maximum Price |
| 2040 | $1002 | $1402 |
| Month | Minimum Price | Maximum Price |
| January | $1002 | $1089 |
| February | $1040 | $1094 |
| March | $1058 | $1113 |
| April | $1069 | $1150 |
| May | $1081 | $1189 |
| June | $1122 | $1231 |
| July | $1138 | $1247 |
| August | $1150 | $1291 |
| September | $1279 | $1331 |
| October | $1291 | $1359 |
| November | $1344 | $1381 |
| December | $1374 | $1402 |
AstraZeneca Stock Price Prediction 2050
By 2050, this company has big plans to excitingly transform healthcare. They want to create new treatments using advanced science, such as specialized cell and gene therapies that can cure health problems at the root.
They also plan to use super-smart computers to help them find new drugs faster and create medicines tailored to everyone. In the future, they hope to find cures for diseases that occur as people get older, braisuch as n problems, an diseases for which we don’t have answers.
The company is a pioneer in using new technology and taking care of the environment, while doing research with AI, which is a kind of smart computer.
If they continue to improve healthcare and buy innovative companies, the entire pharmaceutical industry will become more valuable over time, especially when the world economy strengthens.
Based on their plan, their stock price (the Price of the company’s shares) is expected to be $2602 in 2050.
We believe the stock price will be between $1902 and $2602 in 2050.
| Year | Minimum Price | Maximum Price |
| 2050 | $1902 | $2602 |
| Month | Minimum Price | Maximum Price |
| January | $1902 | $1989 |
| February | $1954 | $2071 |
| March | $2011 | $2091 |
| April | $2031 | $2156 |
| May | $2068 | $2180 |
| June | $2091 | $2191 |
| July | $2131 | $2239 |
| August | $2168 | $2365 |
| September | $2329 | $2381 |
| October | $2361 | $2471 |
| November | $2421 | $2588 |
| December | $2557 | $2602 |
MTNL Share Price Target 2025, 2026, 2030, 2040, 2050
AstraZeneca Stock Ownership Pattern
| Investor Type | Percentage (%) |
|---|---|
| Mutual Funds | 12.6% |
| Other Institutional Investors | 17% |
| ETFs | 0.86% |
| Public Companies and Individual Investors | 70.66% |
Should I buy AstraZeneca Stock?
Buying shares in this company could be a good idea for the future because they have many new medicines, primarily for cancer and rare diseases, and they are expected to grow a lot.
The company is doing well with its money and is always trying to create new medicines. They also pay out some cash to their investors regularly.
Many people own stakes in AstraZeneca, holding about 70.66% of the company. Large groups called mutual funds own about 12.6%, and other groups like ETFs own smaller stakes.
This shows that a lot of ordinary people are interested in the company. However, there are also some risks, such as other companies competing with them, government regulations that may change, and problems getting supplies.
AstraZeneca could be a good choice if you want to invest your money in a company that many people support.
AstraZeneca Stock Earnings Results(USD)
| Indicator | Jun ’24 | Mar ’24 | Dec ’23 | Sep ’23 | Jun ’23 | Mar ’23 | Mar ’23 |
|---|---|---|---|---|---|---|---|
| Operating Revenue | 13,566 | 12,939 | 12,680 | 12,025 | 11,493 | 11,417 | 10,880 |
| Cost of Revenue | 3,082 | 2,184 | 2,219 | 2,309 | 2,096 | 1,961 | 1,906 |
| Gross Profit | 10,485 | 10,756 | 10,462 | 9,717 | 9,398 | 9,457 | 8,975 |
| Operating Expenses | 8,379 | 8,010 | 7,347 | 7,713 | 7,444 | 7,001 | 6,667 |
| Operating Profit | 2,107 | 2,747 | 3,116 | 2,005 | 1,955 | 2,457 | 2,309 |
| Profit Before Tax | 1,829 | 2,398 | 2,801 | 898 | 1,653 | 2,089 | 2,263 |
| Tax | 396 | 470 | 621 | -63 | 275 | 269 | 459 |
| Net Income Common Stockholders | 1,430 | 1,928 | 2,180 | 961 | 1,375 | 1,819 | 1,804 |
| Basic EPS | 0.6 | 0.7 | 0.8 | 0.4 | 0.4 | 0.7 | 0.7 |
| Number of Shares End | 3,101 | 3,101 | 3,099 | 3,099 | 3,099 | 3,101 | 3,099 |
| Net Income Cont./Disc. Operations | 1,430 | 1,928 | 2,180 | 961 | 1,375 | 1,819 | 1,804 |
| Normalized Income | 1,440 | 1,928 | 2,180 | 1,552.3 | 1,375 | 1,819 | 1,611.2 |
| Interest Income | 184 | 101 | 112 | 66 | 102 | 65 | 79 |
| Interest | 458 | 444 | 414 | 409 | 393 | 432 | 366 |
| Net Interest Income | -275 | -344 | -303 | -344 | -292 | -368 | -288 |
| EBIT | 2,286 | 2,841 | 3,214 | 1,306 | 2,045 | 2,520 | 2,628 |
| EBITDA | 4,103 | 4,120 | 4,469 | 2,180 | 3,327 | 3,796 | 4,130 |
| Reconciled Cost of Revenue | 3,082 | 2,184 | 2,219 | 2,309 | 2,096 | 1,961 | 1,906 |
| Reconciled Depreciation | 1,818 | 1,280 | 1,256 | 875 | 1,283 | 1,277 | 1,503 |
| Profit from Continuing Operations | 1,829 | 2,398 | 2,801 | 898 | 1,653 | 2,089 | 2,263 |
| Normalized EBITDA | 4,103 | 4,120 | 4,469 | 2,910 | 3,327 | 3,796 | 3,889 |
Key Metrics Table
| Metric | Value |
| Total Revenue (H1 2024) | $25,618 million |
| Product Sales Growth | 19% |
| Alliance Revenue Growth | 51% |
| Collaboration Revenue Change | -79% |
| Core Product Sales Gross Margin | 81% |
| Core Operating Margin | 34% |
| Core EPS (H1 2024) | $4.04 |
| Reported EPS (H1 2024) | $2.66 |
| Core Tax Rate | 21% |
| Dividend Per Share (FY 2024) | $3.11 |
Peer Comparisons
| Company | Current Price ($) | Market Cap ($M) | PE TTM | ROE (%) | Revenue (Qtr $M) | Net Profit (Qtr $M) |
|---|---|---|---|---|---|---|
| AstraZeneca PLC – ADR | 70.77 | 219,433.4 | 33.80 | 15.64 | 13,566 | 1,430 |
| Eli Lilly & Co | 811.09 | 729,416.98 | 87.16 | 48.94 | 11,439.2 | 970.4 |
| Novo Nordisk – ADR | 84.46 | 374,927.12 | 28.5 | 88.08 | 71,312 | 27,302 |
| Johnson & Johnson | 152.16 | 366,319.84 | 27.04 | – | 22,521 | 3,432 |
| AbbVie Inc | 184.9 | 324,978.1 | 64.45 | 35.91 | 14,461 | 1,562 |
| Merck & Co Inc | 99.82 | 249,979.59 | 21.58 | 0.88 | 16,6578 | 3,158 |
| Novartis AG – ADR | 105.72 | 206,832.35 | 12.89 | 29.02 | 13,173 | 3,190 |
Key Performance Indicator
- The company made about 20% more money than before, totaling $39,183 million, as they performed well in the market.
- More people wanted to buy products for different types of treatments, which led to a 19% increase in total sales.
- Cancer treatments increased the company’s earnings by 23%, which shows that they are a leader in helping people with cancer.
- The Margin of 33% shows operational efficiency.
- Our core product sold Marginand, and we made a good profit – 83% of the money we made from selling it was profit. This means that we set a fair price for it.
- The company made more money, and profit per share increased by 12% to $6.13.
- When pharmaceutical companies work together, they can make more money.
- A stable tax rate of 21% means they manage their taxes well and keep things balanced.
- The segment called R&I made 25% more money than before, the most significant increase among all the segments.
- The company’s earnings from cardiovascular drugs increased by 22%, showing that its business is doing well.
Expert Prediction On the Future Of AstraZeneca
AstraZeneca’s earnings from selling medicines have significantly increased. In March 2023, they earned about $11.9 billion; by September 2024, they earned about $14.6 billion.
They also profit more from their work, but taxes and other costs mean they don’t get to keep all that money.
The amount they get for each share of stock remains the same. Experts believe AstraZeneca will grow even more as it creates new medicines, and more people worldwide need healthcare.
Positive & Negative Factors To Invest In AstraZeneca Stock
Positive Factors
- Our extensive portfolio of cancer-fighting drugs is growing rapidly, and we earned 23% more money, showing that we are one of the best people helping people.
- We believe sales will grow approximately 16% to 20% in 2025, a good increase.
- Acquiring Ammolite Pharma and Fusion Pharmaceuticals helped the company become bigger and stronger.
- The plan is to sell enough products by 2030 to generate $81 billion in revenue, up from 2023. Currently, in 2023, products sold totaled $46.8 billion.
- There are about 202 drugs in development, many of which could be developed and used in the future.
Negative Factors
- Major investigations in China could change how business is done in that sector.
- Trials of drugs for lung cancer have not been as successful as hoped.
- Relying too much on other companies to provide us with things can make it harder to meet our needs.
- Sometimes, problems complying with regulations and getting permission to sell a new product can cause delays.
- Drug smuggling poses a threat to the market’s reputation.
Is AstraZeneca Stock Good To Buy? (Bull Case & Bear Case)
Bull Case
- AstraZeneca’s plan to help fight cancer has room to expand and do more good.
- The company primarily sells things that make it more.
- Good I,t eaearned trialesults and official approval h, which helped it sell better and become more popular.
- Trying new types of treatments helps get more money from different places and is safer because you are not relying on just one thing.
- The company’s success and good results excite people about what they can do in 2024.
- They made a lot more money and more profit.
- Talking about fighting cancer, vaccines, and rare diseases.
- More and more people need medicines.
- Careful study and development of new medicines.
Bear Case
- Many companies are trying to sell cancer drugs, so they may have to lower their prices or share their sales.
- Regulations and waiting times to get permission to sell a product can slow down a company’s growth.
- Relying too much on cancer treatments can be risky, as it makes the whole plan too dependent on a single area.
- When prices drop or competition gets tough in the market, it becomes harder for a business to make money.
- Legal problems due to side effects of vaccines can make people think badly of you and cause financial problems.
- Paying a lot of money and owing to others.
- Other companies are trying to do the same thing as we are.
- Legal protection of a particular idea or invention may expire soon.
- The stock price may rise.
Conclusion
AstraZeneca is growing very well because many people want their medicines, and they are working on new, exciting drugs.
But, there are also some problems, such as the prices of their drugs are rising, other companies are making similar drugs, and the possibility that someone could copy their ideas.
This company is a good choice to invest in because it is strong in its market, it has many new ideas to work on, and it wants to grow.
It focuses on helping people with serious illnesses like cancer and rare diseases, and plans to expand worldwide.
People who want to invest money in AstraZeneca should think carefully about how strong the company is and what risks it faces. If you believe AstraZeneca can make new and good medicines, investing may be a good idea, even if things are uncertain.
Even though there are some challenges, the company’s plans for the future show that its value will increase significantly from 2025 to 2050.
Today, we discussed the AstraZeneca Stock Price Prediction. (AstraZeneca Stock Price Prediction 2025, 2026, 2030, 2040, 2050).
Our primary focus will be on the Price of AstraZeneca Stock in the coming years. If you liked this, please give us five stars in the bottom left corner and share it with your friends and family interested in investing in AstraZeneca Stock.
FAQs
Is AstraZeneca an excellent long-term investment?
The company has many new drugs in development, buys other good companies, and focuses on areas where health problems are growing. Because of this, it has a good chance of developing a lot in the future.
They expect sales of $82 billion by 2030 and continue to spend money on research to create even better medicines. This means those who invest in the company can expect it to grow over time.
What makes AstraZeneca different from other pharmaceutical companies?
AstraZeneca is a company that works on drugs that help fight cancer. They focus on creating tailor-made treatments for each individual.
They specialize in creating new drugs and growing by developing or buying other companies. This is what makes AstraZeneca different from other companies.
How does AstraZeneca’s dividend policy benefit investors?
AstraZeneca plans to give away some of its money to the owners of their shares, giving away about 2.24% of its value.
The company makes a lot of money and regularly pays these dividends. This means that people who hold shares can get a steady income, and the value of their shares can increase over time.
What are the main risks of investing in AstraZeneca?
Some significant problems that can affect a drug or company are when their patents (legal rights to sell the drug) run out, rules and regulations change, results of studies testing drugs are not good, or other companies create similar drugs.
Also, things happening in different countries or people wanting lower prices can make it difficult for the company to make money and stay on top.
How does AstraZeneca’s pipeline support future growth?
AstraZeneca is working on creating 202 new medicines, mainly to treat cancer and rare diseases.
They are working closely with other companies and using new technology to help them grow and perform better in the future.
What is AstraZeneca’s stock price prediction for 2025?
It will likely cost between $51 and $112.
Will AstraZeneca’s stock grow in 2026?
Experts believe that Price026 will increase to between $75 and $151.
What drives AstraZeneca’s stock growth?
Developing new ideas, making smart decisions about spending money, and inventing new and better treatments help us move forward and become stronger.
How will AI impact AstraZeneca’s future?
Using intelligent computers to create new medicines will improve research and help companies perform well in the stock market.
Read Also
